Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Authors

Constantine S. Tam, University of Melbourne
Brad S. Kahl, Washington University School of Medicine in St. Louis
et al

Journal

Haematologica

Publication Date

10-13-2020

Volume

106

Issue

9

First Page

2354

Last Page

2363

Document Type

Open Access Publication

DOI

10.3324/haematol.2020.259432

Rights and Permissions

Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Šimkovič M, Österborg A, Trněný M, Tedeschi A, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, Brown JR. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020 Oct 13;106(9):2354-2363. doi: 10.3324/haematol.2020.259432. Obtained from the Haematologica Journal website http://www.haematologica.org.

Recommended Citation

Tam, Constantine S.; Kahl, Brad S.; and et al, "Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion." Haematologica. 106, 9. 2354 - 2363. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11198